Healio

FDA grants fast track designation to vectorized antibody to treat ALS

Please provide your email address to receive an email when new articles are posted on . VTx-002 targets proteins that play a significant role in neurodegenerative disease. Enrollment in and ...
Yahoo Finance

VectorY Therapeutics and Shape Therapeutics Announce Option and License Agreement to Advance Vectorized Antibodies for Neurodegenerative Diseases Using an AAV5-Derived CNS Capsid

AMSTERDAM & BOSTON & SEATTLE, September 18, 2025--(BUSINESS WIRE)--VectorY Therapeutics, a biotechnology company developing innovative vectorized antibody therapies for the treatment of ...
GEN

Going Dutch: VectorY’s $138M Series A to Advance Vectorized Antibody Programs for Neurodegenerative Diseases

Not all drug targets are created equal. For those that result in a tissue-specific gain-of-function, the strategy can be not-so-straightforward. That’s exactly what’s going on in some forms of ...
Business Wire

VectorY Therapeutics Receives FDA Clearance of IND to Proceed with the PIONEER-ALS Phase 1/2 Trial of VTx-002, a First-in-Class Vectorized Antibody Targeting TDP-43 Pathology ...

AMSTERDAM & BOSTON--(BUSINESS WIRE)--VectorY Therapeutics, a leader in vectorized antibody therapies for neurodegenerative diseases, announced today that the U.S. Food and Drug Administration (FDA) ...